{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:24:39Z","timestamp":1772601879980,"version":"3.50.1"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Pancreas"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Positively charged amino acids (AA) such as arginine\/lysine are coinfused with radiolabeled somatostatin analogs to reduce rates of nephrotoxicity. In the phase 3 NETTER-1 trial, commercial AA formulations were used in association with <jats:sup>177<\/jats:sup>Lu\u2013DOTA-0-Tyr3-Octreotate (DOTATATE). These formulations were also used in an early-access program (EAP) before regulatory approval of <jats:sup>177<\/jats:sup>Lu-DOTATATE. Our program transitioned to compounded <jats:sc>l<\/jats:sc>-arginine 2.5%\/<jats:sc>l<\/jats:sc>-lysine 2.5% in 0.9% NaCl after commercial approval of <jats:sup>177<\/jats:sup>Lu-DOTATATE. We sought to compare rates of nausea\/vomiting with arginine\/lysine versus commercial parenteral AA formulations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Rates of nausea\/vomiting of all 20 EAP patients who received commercial AAs (15% Clinisol) were compared with the first 29 patients to receive <jats:sup>177<\/jats:sup>Lu-DOTATATE after commercial approval and coinfused with arginine\/lysine. Other parameters reviewed included infusion rates, need for PRN nausea medications, and other toxicities.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Seventeen percent of patients who received compounded arginine\/lysine experienced nausea, compared with 100% of patients in the EAP group (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001). Infusion-related reactions occurred in 3% of the arginine\/lysine cohort versus 35% in the EAP group. Infusion durations were substantially shorter in the arginine\/lysine cohort (reduced by 61%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Coinfusions of arginine\/lysine with radiolabeled somatostatin analogs result in substantially lower rates of nausea\/vomiting compared with commercial AA formulations designed for parenteral nutrition.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mpa.0000000000001795","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T19:37:55Z","timestamp":1620070675000},"page":"513-515","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of Nausea and Vomiting Associated With Amino Acid Formulations Coinfused With Peptide Receptor Radionuclide Therapy"],"prefix":"10.1097","volume":"50","author":[{"given":"Taymeyah","family":"Al-Toubah","sequence":"first","affiliation":[{"name":"Department of GI Oncology, H Lee Moffitt Cancer Center and Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhiraj","family":"Sikaria","sequence":"additional","affiliation":[{"name":"Morsani College of Medicine, USF Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Jesurajan","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Loma Linda University, Loma Linda, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Bottiglieri","sequence":"additional","affiliation":[{"name":"Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johnna","family":"Smith","sequence":"additional","affiliation":[{"name":"Diagnostic Imaging and Interventional Radiology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Pell\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai","family":"Hutchinson","sequence":"additional","affiliation":[{"name":"Department of GI Oncology, H Lee Moffitt Cancer Center and Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Strosberg","sequence":"additional","affiliation":[{"name":"Department of GI Oncology, H Lee Moffitt Cancer Center and Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1149-263X","authenticated-orcid":false,"given":"Ghassan","family":"El-Haddad","sequence":"additional","affiliation":[{"name":"Diagnostic Imaging and Interventional Radiology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250812","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ecl.2018.04.005","article-title":"Peptide receptor radiotherapy comes of age","volume":"47","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"key":"bib2-20250812","doi-asserted-by":"crossref","first-page":"16932","DOI":"10.18632\/oncotarget.24524","article-title":"Results and adverse events of personalized peptide receptor radionuclide therapy with 90yttrium and 177lutetium in 1048 patients with neuroendocrine neoplasms","volume":"9","year":"2018","journal-title":"Oncotarget"},{"key":"bib3-20250812","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1007\/s00259-009-1196-8","article-title":"Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours","volume":"36","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib4-20250812","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s00259-005-1793-0","article-title":"Localisation and mechanism of renal retention of radiolabelled somatostatin analogues","volume":"32","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib5-20250812","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s00259-009-1282-y","article-title":"Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues","volume":"37","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20250812","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00259-002-0982-3","article-title":"Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine","volume":"30","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib7-20250812","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000001795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:06:08Z","timestamp":1754957168000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000001795"}},"subtitle":["Commercial Parenteral Nutrition Formulas Versus Compounded Arginine\/Lysine"],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0000000000001795","relation":{},"ISSN":["1536-4828","0885-3177"],"issn-type":[{"value":"1536-4828","type":"electronic"},{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}